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Abstract
Background: It is unclear whether mild to moderate iron overload in liver diseases
other than hereditary haemochromatosis (HH) contributes to hepatocellular
carcinoma. This study examined the association between hepatic iron grade and
hepatocellular carcinoma in patients with end-stage liver disease of diverse
aetiologies. Methods: The prevalence of hepatic iron overload and hepatocellular
carcinoma was examined in 5224 patients undergoing liver transplantation.
Explant pathology reports were reviewed for the underlying pathological diag-
nosis, presence of hepatocellular carcinoma and degree of iron staining. The
distribution of categorical variables was studied using w2 tests. Results: Both iron
overload and hepatocellular carcinoma were the least common with biliary
cirrhosis (1.8 and 2.8% respectively). Hepatocellular carcinoma was the most
common in patients with hepatitis B (16.7%), followed by those with hepatitis C
(15.1%) and HH (14.9%). In the overall cohort, any iron overload was signifi-
cantly associated with hepatocellular carcinoma (P = 0.001), even after adjustment
for the underlying aetiology of liver disease. The association between hepatic iron
content and hepatocellular carcinoma was the strongest in patients with biliary
cirrhosis (Po 0.001) and hepatitis C (Po 0.001). Conclusions: Iron overload is
associated with hepatocellular carcinoma in patients with end-stage liver disease,
suggesting a possible carcinogenic or cocarcinogenic role for iron in chronic liver
disease.
Background
The incidence of hepatocellular cancer (HCC) is
rising, and it is currently the sixth most common
malignancy worldwide (1). HCC carries a poor prog-
nosis and is the major cause of liver-related death in
patients with compensated cirrhosis, accounting for
almost 600 000 deaths annually (1). Various aetio-
logical factors associated with HCC include advanced
age, male gender, non-Caucasian ethnicity, hepatitis B
or C infection, alcoholic cirrhosis, hereditary haemo-
chromatosis (HH) and exposure to aflatoxin (1–14).
Contributed equally to this manuscript.
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Epidemiological studies also suggest a positive
relationship between elevated body iron stores and
cancer (15, 16). This supports the concept that iron
may have a generalized role in carcinogenesis (17, 18).
Excess iron is also considered a potential carcinogen
in the liver. For example, the risk of HCC is markedly
increased in patients with HH. Several studies from
referral centres have reported an approximately 8–10%
incidence of HCC among patients with HH, mostly
in cirrhotic patients (19–22), and have estimated a
100–200-fold increase in risk over the general
population. In a population-based study using death
certificate data, the prevalence of liver cancer was
increased 24-fold in association with a death certi-
ficate diagnosis of HH (23). A Swedish study found a
1.7-fold increase in the incidence of HCC in
patients with HH (24). Additional risk factors such
as hepatitis B, older age and alcohol abuse may
be synergistic with iron overload in increasing the
risk for HCC among cirrhotic patients with
HH (25).
Excess hepatic iron is common in patients with
end-stage liver disease from aetiologies other than
HCC, such as hepatitis C or alcohol use (26–30). Some
have hypothesized that hepatic iron overload may
also be an independent risk factor for development
of hepatocellular carcinoma in these patients (31).
HCC can develop in non-cirrhotic patients with HH,
and increased hepatic iron has been reported in
HCC patients without cirrhosis or HH, suggesting
that iron may play an independent role in hepatic
carcinogenesis (32–34). Supporting this hypothesis,
Borgna-Pignatti et al. (35) reported that patients with
transfusional iron overload owing to underlying b-
thalassaemia are at increased risk of HCC compared
with the general population. Similar findings have
been reported in patients with African iron overload,
even after adjustment for age, gender, hepatitis B and
C, alcohol, aflatoxin and the presence of portal fibrosis
or cirrhosis (36, 37). However, the role of mild to
moderate hepatic iron deposition in hepatic carcino-
genesis in patients with non-HH liver disease remains
unclear.
The aims of this study were to determine the
prevalence of hepatic iron overload in patients
with end-stage liver disease of varying aetiologies
and to examine the association of hepatic iron over-
load with hepatocellular carcinoma. Understanding
this relationship may provide valuable data for
understanding hepatic carcinogenesis and for devel-
opment of strategies to treat iron overload and
screen for HCC in patients with end-stage liver
disease.
Methods
The National Hemochromatosis Transplant Registry
(NHTR) is the result of an ongoing collaboration
between 22 liver transplant centres in the US with data
compilation beginning in 1990. Fourteen of the 22
centres in the NHTR participated in this study (Baylor
University, Cleveland Clinic, Columbia University,
California Pacific Medical Center, Mayo Clinic, Med-
ical College of Virginia, University of Michigan, Rush
University, Mount Sinai, Saint Louis University, Stan-
ford University, University of California Los Angeles,
University of California San Francisco and University
of Nebraska). Anonymized explant pathology reports
without any private health information of all patients
undergoing a first liver transplantation for end-stage
liver disease were sent to the Data Repository at the
University of Washington during the inclusive period
of this study (1 January 1990–December 1996). This
study was approved by the Institutional Review Board
at the University of Washington, and each individual
centre complied with local institutional guidelines to
provide data to the NHTR.
We conducted a retrospective review of explant
pathology reports in the NHTR database. Patients
undergoing their first liver transplant between 1990
and 1996 were considered for this study. Patients
were excluded if: (i) age o 18 years at the time of
transplantation, (ii) acute or fulminant hepatic
failure without cirrhosis, (iii) undergoing retransplan-
tation, (iv) primary indication for transplantation
was amyloidosis, polycystic liver disease or liver
metastasis from non-hepatobiliary cancer and/or (v)
insufficient data in the registry database. We also
excluded patients in whom hepatic iron quantification
was not performed. From the eligible pathology re-
ports, we extracted data about year of transplantation,
pretransplant diagnosis of liver disease, post-trans-
plant diagnosis from the explant pathology report
and degree of hepatic iron deposition. The presence
or absence of HCC was also determined from the
pathology reports. Because data for this study were
obtained from the explant pathology reports, data
about age, gender and prior blood transfusions were
not always available for analysis. For this study, sub-
jects’ liver disease was determined from the pathology
report and classified into:
1. Biliary cirrhosis – primary biliary cirrhosis, pri-
mary sclerosing cholangitis and other biliary dis-
orders including biliary atresia, Caroli’s disease,
secondary cholestasis, cystic fibrosis, systemic lupus
erythematosus, triaditis and Von Meyenburg dis-
ease.
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2. Viral cirrhosis – hepatitis C, hepatitis B, hepatitis B
and hepatitis C co-infection and other unspecified
viral infection.
3. Alcoholic cirrhosis – alcohol alone, or alcohol with
viral coinfection.
4. Autoimmune hepatitis.
5. Metabolic – a-1-antitrypsin deficiency, HH,
Wilson’s disease.
6. Other chronic liver disease – cryptogenic, non-
alcoholic fatty liver disease, other/unspecified
(including fibrosis, metastatic non-hepatic malig-
nancy, haemangioma, hepatoportal sclerosis,
ischaemia, portal vein thrombosis).
7. Cancer without other liver disease – hepatocellular
carcinoma, cholangiocarcinoma.
Hepatic iron content was documented on the
pathology reports by a histological semi-quantitative
grade on a scale of 0–41 where 0 represented a
complete absence of stainable iron and 41 represented
hepatic iron visible on slides to the naked eye (38).
Within each aetiological category of liver disease,
hepatic iron staining was subclassified into three
categories: no iron (0); mild iron (1–21); and moder-
ate to severe iron (3–41). Because the time period of
this study predates the identification of the HFE gene,
HFE mutation status in the study subjects was un-
known. Hepatic iron staining, where available, was
performed using Perl’s prussian blue and scored as
described previously (38)
Data analysis
We examined the pattern of iron deposition in the
liver in patients with and without HCC, both in the
overall population and within categories of liver dis-
ease aetiology. The distribution of categorical variables
was expressed as a binomial proportion. Differences in
the distribution of categorical variables were com-
pared using the w2 test. A P-value o 0.05 was
considered to be statistically significant. We used
logistic regression analysis to examine the association
of iron staining with HCC after adjustment for other
variables.
Results
Of the 5320 subjects who underwent orthotopic liver
transplantation in the study period, 96 were excluded
and data were extracted from each of the 5224
remaining reports. The post-transplantation diag-
noses, degree of iron staining and proportion of
patients with HCC are shown in Table 1. Viral
hepatitis was the most common aetiology of liver
disease, followed by alcoholic liver disease (with or
without coexisting viral infection) and biliary cirrho-
sis. HH was uncommon in this study population.
Mild and excess iron staining were found in 5.6 and
2.8% of the study population respectively (Table 1).
Iron staining was the least common in patients with
biliary cirrhosis (2.6%), but the most common in
patients with HH (91.9%) and alcoholic cirrhosis
(14.3%).
Hepatocellular cancer was the most common in
patients with viral infection (15.6%), and the least
common in patients with biliary cirrhosis (1.8%)
(Table 1).
Table 2 shows the grade of iron staining in patients
with or without HCC. There was a strong trend
towards increased iron staining in patients with HCC
in the overall population (P = 0.06), and a significant
association of HCC with increased iron staining in
patients with biliary cirrhosis (Po 0.001) or viral
hepatitis (P = 0.008). The association of stainable iron
with HCC was the strongest in patients with hepatitis
C infection (Po 0.001), but was also present in
patients with primary biliary cirrhosis (P = 0.01),
other biliary tract disease (P = 0.02) and in patients
with cryptogenic cirrhosis (P = 0.04). The apparent
lack of association of iron with HCC in the HH
category may be because of the high prevalence of iron
overload in HH patients without HCC.
Finally, we used logistic regression to examine
whether hepatic iron is a risk factor for HCC, inde-
pendent of the underlying liver disease (Table 3). Our
results showed that the risk of HCC was increased with
both mild (odds ratio 1.59; 95% confidence interval
1.07, 2.38) and excess (odds ratio 2.10, 95% confi-
dence interval 1.25, 3.42) iron deposition, even after
adjustment for the aetiology of underlying liver dis-
ease. Consistent with prior data, the prevalence of
HCC was the highest in patients with viral cirrhosis
(compared with biliary cirrhosis: odds ratio 9.92, 95%
confidence interval 6.35, 15.5).
Discussion
We found that the prevalence of hepatic iron overload
at transplantation differs by the aetiology of liver
disease, and that hepatic iron overload is associated
with an increased prevalence of HCC. To our know-
ledge, this is the largest study examining the relation-
ship between iron overload and HCC in patients with
diverse aetiologies of liver disease. Similar to previous
reports, we found a low prevalence of iron overload in
biliary cirrhosis compared with non-biliary cirrhosis
(37, 39, 40). Also in concordance with previous
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epidemiological reports, HCC was most prevalent in
cirrhotics with viral hepatitis B, hepatitis C and HH
but uncommon in biliary cirrhosis (41). Our findings
suggest that excess iron may assist in carcinogenesis in
the cirrhotic liver.
Various carcinogenic or cocarcinogenic mechanisms
for iron have been proposed. Non-transferrin-bound
free iron may promote carcinogenesis by promoting
production of reactive oxygen species, leading to point
mutations or structural damage to chromosomes
(strand breaks) (42–44). Inactivation of tumour sup-
pressor genes such as p53 may thus occur (45, 46).
Because experimental iron overload does not induce
hepatic cancer in normal laboratory animals, it is
possible that iron may not cause but may assist
carcinogenesis (47). Non-transferrin-bound free iron
and ferritin may also impair lymphocyte proliferation
(47) and decrease tumoricidal activity of macrophages
(48). As an essential substrate for cellular proliferation,
addition of iron promotes DNA synthesis in rat
hepatocyte cell cultures (49). Iron also increases cell
proliferation in hepatoma cell lines, while iron deple-
tion causes tumour cell death (50). Other possible
carcinogenic mechanisms include increased produc-
tion of nitric oxide synthase 2 observed in HH patients
with HCC (45). Excess production of nitric oxide by
this enzyme may initiate or aid carcinogenesis by
enhancing lipid peroxidation and impairing DNA
repair (51, 52). Furthermore, iron overload may
indirectly promote hepatic carcinogenesis by enhan-
cing fibrogenic effects of lipid peroxidation and
activating stellate cells, thus causing accelerated pro-
gression to cirrhosis (52).
In our study, the presence of iron overload was
associated with HCC in patients with viral and biliary
cirrhosis, but was not significantly associated in pa-
tients with alcoholic liver disease or HH. However,
some patients with cirrhosis from viral or other
aetiologies may have had concomitant alcoholic liver
disease not noted on the pathology reports, and we did
Table 1. Stainable iron or hepatocellular carcinoma in explant livers classified by pathological diagnosis
Category of pathological diagnosis (N)
Iron, N (%)
Hepatocellular carcinoma
present, N (%)No iron Mild ironw Excess ironz
All patients (5224) 4788 (91.6) 291 (5.6) 145 (2.8) 482 (9.2)
Biliary cirrhosis (1212) 1179 (97.2) 27 (2.2) 7 (0.6) 22(1.8)
PBC (541) 527 (97.4) 11 (2.0) 3 (0.6) 16 (3.0)
PSC (527) 517 (98.1) 8 (1.5) 2 (0.4) 3 (0.6)
Other biliary (144) 134 (93.1) 8 (5.6) 2 (1.4) 2 (1.4)
Viral cirrhosis (1367) 1305 (95.5) 39 (2.8) 23 (1.7) 214 (15.6)
HCV (1052) 1031 (98.0) 11 (1.0) 10 (1.0) 159 (15.1)
HBV (300) 260 (86.7) 28(9.3) 12 (4.0) 50 (16.7)
HCV1HBV (4) 4 (100.0) 0 (0.0) 0 (0.0) 4 (100.0)
Viral unspecified (11) 10 (90.9) 0 (0.0) 1 (9.1) 1 (9.1)
Alcoholic cirrhosis (870) 746 (85.7) 86 (9.9) 38 (4.4) 46 (5.3)
Alcohol (663) 569 (85.8) 67 (10.1) 27 (4.1) 33 (5.0)
Alcohol1viral (207) 177 (85.5) 19 (9.2) 11(5.3) 13 (6.3)
Autoimmune hepatitis (192) 184 (95.8) 5 (2.6) 3 (1.6) 1 (0.5)
Metabolic (214) 130 (60.8) 38 (17.8) 46 (21.5) 16 (7.5)
A1AT deficiency (102) 90 (88.2) 9 (8.8) 3 (2.9) 5 (4.9)
Haemochromatosis (74) 6 (8.1) 27 (36.5) 41 (55.4) 11 (14.9)
Wilson’s disease (38) 34 (89.5) 2 (5.3) 2 (5.3) 0 (0.0)
Other chronic liver disease (1282) 1160 (90.5) 94 (7.3) 28 (2.2) 114 (8.9)
Cryptogenic (1175) 1064 (90.6) 86 (7.3) 25 (2.1) 113 (9.6)
NASH (35) 32 (91.4) 2 (5.7) 1 (2.9) 1 (2.9)
Other (72) 64 (88.9) 6 (8.3) 2 (2.8) 0 (0.0)
Cancer only (86) 84 (97.7) 2 (2.3) 0 (0.0) 69 (80.2)
HCC (69) 68 (98.6) 1 (1.4) 0 (0.0) 69 (100)
Cholangiocarcinoma (17) 16 (94.1) 1 (5.9) 0 (0.0) 0 (0.0)
No stainable iron.
wMild stainable iron, 1–21.
zModerate to severe iron, 3–41.
A1AT, a-1-antitrypsin; HBV, hepatitis B virus; HCC, hepatocellular cancer; HCV, hepatitis C virus; NASH, non-alcoholic steatohepatitis; PBC, primary
biliary cirrhosis; PSC, primary sclerosing cholangitis.
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not have data about alcohol consumption in our
patients. The lack of association of hepatic iron with
HCC in patients with HH may be owing to the high
overall prevalence of iron overload in these patients.
The small number of patients with metabolic liver
disease other than HH likely limited our statistical
power to detect an association. Within the patients
with viral hepatitis, the association of iron and HCC
was seen primarily in patients with hepatitis C, while
there was no significant association in patients with
hepatitis B. It is notable that iron overload was a risk
factor for HCC in patients with biliary cirrhosis,
despite the low prevalence of both HCC and iron
overload in this population. Likewise, HCC was less
common in patients with other chronic liver diseases
(primarily cryptogenic cirrhosis), but even so iron
overload appeared to be associated with HCC in this
patient group.
Our results confirm previously published studies
examining iron overload and HCC. For example,
Chapoutot et al. (46) estimated hepatic iron in liver
biopsies from 104 hepatitis C cirrhotics – 48 with HCC
Table 3. Logistic model of risk factors for hepatocellular
carcinoma
Odds ratio 95% CI P-value
Iron 0.02
None Referent –
Mild 1.59 1.07, 2.38
Excess 2.10 1.25, 3.52
Disease category o 0.001
Biliary Referent – –
Viral 9.92 6.35, 15.5
Alcohol 2.79 1.66, 4.69
Autoimmune 0.28 0.04, 2.09
Metabolic 3.34 1.69, 6.65
Other 5.06 3.181, 8.06
CI, confidence interval.




(n = 4742), N (%)
Hepatocellular carcinoma
(n = 482), N (%)
P-valueNo iron Mild ironw Excess ironz No iron Mild ironw Excess ironz
All patients (5224) 4359 (91.9) 258 (5.4) 125 (2.6) 429 (89.0) 33 (6.9) 20 (4.1) 0.06
Biliary cirrhosis (1212) 1160 (97.4) 24 (2.0) 7 (0.6) 19 (84.4) 3 (13.6) 0 (0.0) 0.001
PBC (541) 513 (97.7) 9(1.7) 3 (0.6) 14 (87.5) 2 (12.5) 0 (0.0) 0.01
PSC (527) 514 (98.1) 8 (1.5) 2 (0.4) 3 (100.0) 0 (0.0) 0 (0.0) 0.97
Other biliary (144) 133 (93.7) 7 (4.9) 2 (1.4) 1 (50.0) 1 (50.0) 0 (0.0) 0.02
Viral cirrhosis (1367) 1109 (96.2) 29 (2.5) 15 (1.3) 196 (91.6) 10 (4.7) 8 (3.7) 0.008
HCV (1052) 884 (99.0) 4 (0.4) 5 (0.6) 147 (92.4) 7 (4.4) 5 (3.1) o 0.001
HBV (300) 216 (86.4) 25 (10.0) 9 (3.6) 44 (88.0) 3 (6.0) 3 (6.0) 0.51
HCV1HBV (4) – – – 4 (100.0) 0 (0.0) 0 (0.0) –
Viral unspecified (11) 9 (90.0) 0 (0.0) 1 (10.0) 1 (100.0) 0 (0.0) 0 (0.0) 0.74
Alcoholic cirrhosis (870) 703 (85.3) 83 (10.1) 38 (4.6) 43 (93.5) 3 (6.5) 0 (0.0) 0.21
Alcohol (663) 538 (85.4) 65 (10.3) 27 (4.3) 31 (93.9) 2 (6.1) 0 (0.0) 0.33
Alcohol1viral (207) 165 (85.0) 18 (9.3) 11 (5.7) 12 (92.3) 1 (7.7) 0 (0.0) 0.66
Autoimmune hepatitis (192) 183 (95.8) 5 (2.6) 3 (1.6) 1 (100) – – 0.98
Metabolic (214) 124 (62.6) 35 (17.7) 39 (19.7) 6 (37.5) 3 (18.8) 7 (43.7) 0.06
A1AT deficiency (102) 85 (87.6) 9 (9.3) 3 (3.1) 5 (100.0) 0 (0.0) 0 (0.0) 0.70
Haemochromatosis (74) 5 (7.9) 24 (38.1) 34 (54.0) 1 (9.1) 3 (27.3) 7 (63.6) 0.78
Wilson’s disease (38) 34 (89.5) 2 (5.3) 2 (5.3) – – – –
Other chronic liver disease (1282) 1064 (91.1) 81 (6.9) 23 (2.0) 96 (84.2) 13 (11.4) 5 (4.4) 0.05
Cryptogenic (1175) 969 (91.2) 73 (6.9) 20 (1.9) 95 (84.1) 113 (11.5) 5 (4.4) 0.04
NASH (35) 31 (91.2) 2 (5.9) 1 (2.9) 1 (100.0) 0 (0.0) 0 (0.0) 0.95
Other (72) 64 (88.9) 6 (8.3) 2 (2.8) – – – –
Cancer only (86) 16 (94.1) 1 (5.9) 0 (0.0) 68 (98.6) 1 (1.4) 0 (0.0) 0.28
HCC (69) – – – 68 (98.6) 1 (1.4) 0 (0.0) –
Cholangiocarcinoma (17) 16 (94.1) 1 (5.9) 0 (0.0) – – – –
No stainable iron.
wMild stainable iron, 1–21.
zModerate to severe iron, 3–41.
P-values compare distribution of iron staining in patients with and without hepatocellular carcinoma.
A1AT, a-1-antitrypsin; HBV, hepatitis B virus; HCC, hepatocellular cancer; HCV, hepatitis C virus; NASH, non-alcoholic steatohepatitis; PBC, primary
biliary cirrhosis; PSC, primary sclerosing cholangitis.
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and 56 controls without HCC. Hepatic iron deposition
was more prevalent and more significant in patients
with HCC than in control patients without HCC,
suggesting that iron excess may be a cofactor in hepatic
carcinogenesis (46). Ito et al. (53), evaluated magnetic
resonance images for diffuse hepatic iron deposition
and iron deposition in regenerative hepatic nodules in
196 cirrhotic patients with and without HCC (n = 80
and 116 respectively). HCC was more common in
patients with siderotic regenerative nodules than in
patients without iron in regenerative nodules. They
hypothesized that iron may be causally linked to HCC
in this population. In contrast, Ebara et al. (54)
studied the association of copper, zinc and iron with
HCC in cirrhotics with hepatitis C. Metal content was
quantified in non-HCC liver parenchyma and in
malignant nodules of 112 patients with HCC, in seven
patients with dysplastic nodules and in 12 patients
without HCC. No significant differences in hepatic
iron concentrations were found in patients with and
without HCC, although the relatively small number of
patients without HCC may have impaired the statis-
tical power of this study. In this study, iron was
quantified using particle-induced X-ray emission,
rather than using semiquantitative measures as in our
study. However, this method likely measures all types
of hepatic iron, rather than just haemosiderin, which
appears to be most closely associated with HCC.
Our study has some limitations. Because the data
collection predates HFE genotyping, genotype data
were not available for analysis. We did not have direct
measurements of hepatic iron concentrations, but
instead relied on semiquantitative iron grading in
explant specimens. Because we relied primarily on
pathology reports, additional clinical and laboratory
data such as age, gender, history of blood transfusions,
history of haemolytic diseases, duration of liver dis-
ease, prior alcohol intake and routine laboratory
measurements were not consistently available. We
therefore could not include these variables in our
model, and some of the associations of iron and
HCC in our study may be related to confounding of
our results by these variables. For example, excess
iron deposition in the liver may occur with longer
disease duration, which could also increase the risk of
HCC.
We were only able to study patients with end-stage
liver disease who survived to liver transplantation, and
our results may not necessarily apply to other patients
with end-stage liver disease. Our study dates back to
1990, and it is possible that hepatitis C infection was
under-diagnosed in this cohort. Finally, there is sig-
nificant variability in hepatic iron deposition in end-
stage liver disease (55). We were able to obtain tissue
from explanted livers, minimizing sampling variabil-
ity, but we cannot account for biological variability in
iron deposition. Nevertheless, the large size of our
tissue samples and the similarity of our results to prior
reports (27) suggest that such variability did not
significantly affect our results.
In summary, our findings support earlier evidence
that iron overload is associated with HCC in patients
with end-stage liver disease of diverse aetiologies. The
association between iron overload and HCC was the
strongest in patients with viral hepatitis and biliary
tract disease. Similar to previous studies, we found
that iron overload is common in patients with alco-
holic liver disease, but relatively uncommon in pa-
tients with biliary cirrhosis. Additional studies are
necessary to identify the mechanistic role of iron in
initiating or promoting HCC in cirrhotic patients, and
to determine whether iron acts independently of
potential confounders such as age, alcohol intake and
disease duration. Because HCC is common and incurs
high morbidity and mortality, measures to prevent
HCC in patients with end-stage liver disease are clearly
needed. Our results also suggest that treatment of iron
overload, such as with phlebotomy, may have some
benefits in decreasing the burden of HCC in this
patient population. Additional prospective studies will
further clarify the relationships among iron deposi-
tion, HFE genotypes and hepatocellular carcinoma in
patients with diverse aetiologies of liver disease.
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